Pune, India -- (SBWIRE) -- 05/22/2018 -- Avail 10% Discount on Direct Purchase "Global Point-of-Care Testing Market" Or kindly send the email at sopan.gedam@databridgemarketresearch.com
Global Point-of-Care Testing (POCT) Market is projected to reach 38.2 billion by 2024, from USD 18.5 billion in 2016 growing at a CAGR of 9.5% during the forecast period of 2017 to 2024 The actual calculation year for the report in 2016, while the historic data is for 2015 and the forecast period is still 2024.
Click Here For Free Sample Report @: http://databridgemarketresearch.com/request-a-sample/?dbmr=point-care-testing-poct-market
Some Key Players:
Other players in this market include Beckman Coulter, Inc., Becton, Dickinson and Company, Johnson & Johnson, Alere Inc., Instrumentation Laboratory, PTS Diagnostics, Abaxis, Inc., Medtronic, Accriva Diagnostics, OPTI Medical, Sienco, Inc., Alpha Scientific, AccuBioTech Co., Ltd., ACON Laboratories, Inc., Acrongenomics, Inc, bioMérieux SA, Biomerica, Inc., Atlas Genetics Ltd., Alfa Scientific Designs, Inc., Bio-Rad Laboratories, Inc., Medica Corporation, and Nova Biomedicaamong others holds 53.1% of the global injectable drug delivery market in 2016.
F. HOFFMANN-LA ROCHE LTD:
Historical Background – Roche was established in 1896
Nature of Business: F. Hoffmann-La Roche Ltd., is one of the largest biotech company with 17 biopharmaceuticals on the market. The company is operating in more than 100 countries around the globe. Some of the subsidiaries are Genetech, Roche Diagnostics, Chugai Pharmaceutical Co., Ventana Medical Systems, InterMune, Inc., Syntex, Anadys Pharmaceuticals, Roche Applied Science, Bioveris, Roche products, Inc., Roche pharma AG, Pt Roche Indonesia, Bina Technologies, Inc., nv Roche sa, Roche SAS, Roche Glycart AG, Roche Co., Ltd.
Main focus: Since the establishment in 1896, the company's main focus is on oncology, immunology, ophthalmology, infectious diseases and neuroscience.
Main Business Areas: Pharmaceuticals and Diagnostics.
Recent Developments:
1. In August 2016,Roche Diagnostics Ltd., received FDA approval for cobas Influenza A/B & RSV test for the cobasLiat System that differentiates flu and Respiratory Syncytial Virus (RSV) in 20 minutes
2. In May 2015, Roche Diagnostics Ltd., received FDA CLIA Waiver for the cobasLiat PCR System and Strep A assay to test Strep A in throat swab specimen.
3. In December 2014, Roche Diagnostics Ltd, received FDA approval for LightMix Ebola Zaire rRT-PCR Test at the time of emergency to treat Ebola Zaire virus infection.
Any specific requirements are you looking for? Ask to your Industry Experts@: http://databridgemarketresearch.com/inquire-before-buying/?dbmr=point-care-testing-poct-market
Global Point-of-Care Testing (POCT) Market: Recent Developments
The demand for point-of-care testing (POCT) is growing due to the value-shift in healthcare and increasing technological advancements. Also, the rising prevalence of lifestyle and infectious diseases, early detection of diseases, and management of multiple chronic conditions is fueling the growth of the market. Some of the other factors contributing to the growth of the market are Private investments and venture funding, new product development and government support, increasing adoption of POC devices, and miniaturization of devices. On the other hand, factors such as pricing pressure, low reimbursement, and XX are restraining the growth of the market.
Factors such as emerging market, growing patient pool, rising number of partnerships and joint ventures, and rising initiatives by the market players will contribute to the growth of the market in future. Also, the current focus of the companies on the development of devices for diagnosis and treatment of cancer, stroke, and cardiac patients will drive the market in future. To compete with other POCT companies in the future, POCT companies will need to employ a different set of digital strategies and connectivity solutions.
Global Point-of-Care Testing (POCT) Market @: Geographic Segmentation
The global point-of-care testing market is highly fragmented with various companies operating in local regions. The major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. For instance, in June 2015, Roche launched its Cardiac point-of-care (POC) troponin test for the cobas h 232 system which is available for countries which accept the CE Mark. This product has improved accuracy at low concentrations and it will help in diagnosis of heart attack patients with high mortality risk. The report includes company share data for different geographies including Global, North America, Europe and APAC.
Based on geography the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and rest of the world. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others.
Any specific requirements are you looking for? Ask to your Industry Experts: http://databridgemarketresearch.com/speak-to-analyst/?dbmr=point-care-testing-poct-market
TABLE OF CONTENTS GLOBAL POINT-OF-CARE TESTING MARKET
1. INTRODUCTION
1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF GLOBAL POINT-OF-CARE TESTING MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED
2. MARKET SEGMENTATION
2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURC
2.8. ASSUMPTIONS
3. MARKET OVERVIEW
3.1. DRIVERS
3.1.1. GROWING GERIATRIC POPULATION
3.1.2. ADVANCEMENT IN TECHNOLOGY
3.1.3. DECENTRALIZED LABORATORY TESTING
3.1.4. INCREASED INCIDENCE OF CHRONIC DISEASES
3.1.5. LABORATORY STAFF SHORTAGES
3.2. RESTRAINTS
3.2.1. UNFAVOURABLE REIMBURSEMENT SCENARIO
3.2.2. ECONOMIC COST
3.3. OPPORTUNITIES
3.3.1. EMERGING MICROFLUIDIC LAB-ON-A-CHIP TECHNOLOGY
3.3.2. EMERGING MARKETS
3.3.3. UNMET MEDICAL NEEDS
3.4. CHALLENGES
3.4.1. LACK OF ACCURACY AND EFFICIENCY
3.4.2. DATA MANAGEMENT AND LACK OF CONNECTIVITY
3.4.3. TESTING PERFORMED BY NON-LABORATORY PERSONNEL AND LACK OF AWARENESS AMONG THE USERS
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
6. GLOBAL POINT-OF-CARE TESTING MARKET: REGULATORY SCENARIO
6.1. OVERVIEW:
6.1.1. REGULATORY PROCEDURE:
7. GLOBAL POINT-OF-CARE TESTING MARKET: REIMBURSEMENT SCENARIO
7.1. OVERVIEW:
8. GLOBAL POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE
8.1. OVERVIEW
8.2. CARDIOMETABOLIC MONITORING KITS
8.2.1. CARDIAC MARKERS
8.2.2. BLOOD GAS ELECTROLYTE TESTING KITS
8.2.3. HBA1C TESTING KITS
8.2.4. LIPID TESTING KITS
8.3. INFECTIOUS DISEASE TESTING KITS
8.3.1. INFLUENZA TESTING KITS
8.3.2. HIV TESTING KITS
8.3.3. HEPATITIS TESTING KITS
8.3.4. STD TESTING KITS
8.3.5. TROPICAL DISEASESTESTING KITS
8.3.6. HEALTHCARE ASSOCIATED TESTING KITS
8.3.7. RESPIRATORY INFECTIONS TESTING KITS
8.4. CHOLESTEROL TESTING KITS
8.4.1. PROTHROMBIN TIME TESTING KITS
8.4.2. ACTIVATED CLOTTING TIME TESTING KITS
8.5. BLOOD GLUCOSE TESTING KITS
8.6. PREGNANCY AND FERTILITY TESTING KITS
8.7. TUMOR CANCER MARKERS
8.8. URINALYSIS TESTING KITS
8.9. HEMATOLOGY TESTING KITS
8.10. DRUGS OF ABUSE TESTING KITS
8.11. FECAL OCCULT TESTING KITS
8.12. RAPID COAGULATION TESTING KITS
9. GLOBAL POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.1.1. DIRECT TENDER
9.1.2. RETAIL PHARMACY
10. GLOBAL POINT-OF-CARE TESTING MARKET, BY END USER
10.1. OVERVIEW
10.2. GLOBAL POCT MARKET: HOSPITALS
10.3. GLOBAL POCT MARKET: CLINICS
10.4. GLOBAL POCT MARKET: AMBULATORY CARE
10.5. GLOBAL POCT MARKET: HOME HEALTHCARE
10.6. GLOBAL POCT MARKET: RESEARCH LABORATORIES
11. GLOBAL POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE
11.1. OVERVIEW
11.2. GLOBAL POCT MARKET: PRESCRIPTION BASED TESTING KITS
11.3. GLOBAL POCT MARKET: OVER THE COUNTER BASED TESTING KITS
12. GLOBAL POINT-OF-CARE TESTING MARKET, BY GEOGRAPHY
12.1. OVERVIEW
12.2. NORTH AMERICA POINT-OF-CARE TESTING MARKET
12.2.1. U.S.POINT-OF-CARE TESTING MARKET
12.2.2. CANADA POINT-OF-CARE TESTING MARKET
12.2.3. MEXICO POINT-OF-CARE TESTING MARKET
12.3. EUROPE POINT-OF-CARE TESTING MARKET
12.3.1. GERMANY POINT-OF-CARE TESTING MARKET
12.3.2. FRANCE POINT-OF-CARE TESTING MARKET
12.3.3. U.K. POINT-OF-CARE TESTING MARKET
12.3.4. ITALY POINT-OF-CARE TESTING MARKET
12.3.5. SPAIN POINT-OF-CARE TESTING MARKET
12.3.6. RUSSIA POINT-OF-CARE TESTING MARKET
12.3.7. TURKEY POINT-OF-CARE TESTING MARKET
12.3.8. BELGIUM POINT-OF-CARE TESTING MARKET
12.3.9. NETHERLANDS POINT-OF-CARE TESTING MARKET
12.3.10. SWITZERLAND POINT-OF-CARE TESTING MARKET
12.3.11. REST OF EUROPE POINT-OF-CARE TESTING MARKET
12.4. APAC POINT-OF-CARE TESTING MARKET
12.4.1. JAPAN POINT-OF-CARE TESTING MARKET
12.4.2. CHINA POINT-OF-CARE TESTING MARKET
12.4.3. SOUTH KOREA POINT-OF-CARE TESTING MARKET
12.4.4. INDIA POINT-OF-CARE TESTING MARKET
12.4.5. AUSTRALIA POINT-OF-CARE TESTING MARKET
12.4.6. SINGAPORE POINT-OF-CARE TESTING MARKET
12.4.7. THAILAND POINT-OF-CARE TESTING MARKET
12.4.8. MALAYSIA POINT-OF-CARE TESTING MARKET
12.4.9. INDONESIA POINT-OF-CARE TESTING MARKET
12.4.10. PHILIPPINES POINT-OF-CARE TESTING MARKET
12.4.11. REST OF APAC POINT-OF-CARE TESTING MARKET
12.5. MEA POINT-OF-CARE TESTING MARKET
12.5.1. SOUTH AFRICA POINT-OF-CARE TESTING MARKET
12.5.2. SAUDI ARABIA POINT-OF-CARE TESTING MARKET
12.5.3. UAE POINT-OF-CARE TESTING MARKET
12.5.4. REST OF MEA POINT-OF-CARE TESTING MARKET
12.6. SOUTH AMERICA POINT-OF-CARE TESTING MARKET
12.6.1. BRAZIL POINT-OF-CARE TESTING MARKET
13. GLOBAL POINT-OF-CARE TESTING MARKET : COMPANY LANDSCAPE
13.1. COMPANY SHARE ANALYSIS: GLOBAL
13.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
13.3. COMPANY SHARE ANALYSIS: EUROPE
13.4. COMPANY SHARE ANALYSIS: APAC
14. COMPANY PROFILES
14.1. JOHNSON AND JOHNSON SERVICES, INC.
14.1.1. COMPANY OVERVIEW
14.1.2. REVENUE ANALYSIS
14.1.3. PRODUCT PORTFOLIO
14.1.4. RECENT DEVELOPMENTS
14.2. BECTON, DICKINSON AND COMPANY
14.2.1. COMPANY OVERVIEW
14.2.2. REVENUE ANALYSIS
14.2.3. PRODUCT PORTFOLIO
14.2.4. RECENT DEVELOPMENTS
14.3. MEDTRONIC
14.3.1. COMPANY OVERVIEW
14.3.2. REVENUE ANALYSIS
14.3.3. PRODUCT PORTFOLIO
14.3.4. RECENT DEVELOPMENTS
14.4. F. HOFFMANN-LA ROCHE LTD
14.4.1. COMPANY OVERVIEW
14.4.2. REVENUE ANALYSIS
14.4.3. PRODUCT PORTFOLIO
14.4.4. RECENT DEVELOPMENTS
14.5. SIEMENS AG
14.5.1. COMPANY OVERVIEW
14.5.2. REVENUE ANALYSIS
14.5.3. PRODUCT PORTFOLIO
14.5.4. RECENT DEVELOPMENTS
14.6. ABBOTT
14.6.1. COMPANY OVERVIEW
14.6.2. REVENUE ANALYSIS
14.6.3. PRODUCT PORTFOLIO
14.6.4. PRODUCT PIPELINE
14.6.5. RECENT DEVELOPMENTS
14.7. DANAHER
14.7.1. COMPANY OVERVIEW
14.7.2. REVENUE ANALYSIS
14.7.3. PRODUCT PORTFOLIO
14.7.4. RECENT DEVELOPMENTS
14.8. WERFENLIFE
14.8.1. COMPANY OVERVIEW
14.8.2. REVENUE ANALYSIS
14.8.3. PRODUCT PORTFOLIO
14.8.4. RECENT DEVELOPMENTS
14.9. HENRY SCHEIN, INC.
14.9.1. COMPANY OVERVIEW
14.9.2. REVENUE ANALYSIS
14.9.3. PRODUCT PORTFOLIO
14.9.4. RECENT DEVELOPMENTS
14.10. OPTI MEDICAL (SUBSIDIARY OF IDEXX LABORATORIES, INC)
14.10.1. COMPANY OVERVIEW
14.10.2. REVENUE ANALYSIS
14.10.3. PRODUCT PORTFOLIO
14.10.4. RECENT DEVELOPMENTS
14.11. SIENCO, INC.
14.11.1. COMPANY OVERVIEW
14.11.2. REVENUE ANALYSIS
14.11.3. PRODUCT PORTFOLIO
14.11.4. RECENT DEVELOPMENTS
14.12. ACON LABORATORIES, INC.
14.12.1. COMPANY OVERVIEW
14.12.2. REVENUE ANALYSIS
14.12.3. PRODUCT PORTFOLIO
14.12.4. RECENT DEVELOPMENTS
14.13. ATIVA MEDICAL CORPORATION
14.13.1. COMPANY OVERVIEW
14.13.2. REVENUE ANALYSIS
14.13.3. PRODUCT PORTFOLIO
14.13.4. RECENT DEVELOPMENTS
14.14. ABAXIS
14.14.1. COMPANY OVERVIEW
14.14.2. REVENUE ANALYSIS
14.14.3. PRODUCT PORTFOLIO
14.14.4. RECENT DEVELOPMENTS
14.15. ARKRAY, INC
14.15.1. COMPANY OVERVIEW
14.15.2. REVENUE ANALYSIS
14.15.3. PRODUCT PORTFOLIO
14.15.4. RECENT DEVELOPMENTS
14.16. AERSCHER DIAGNOSTICS, LLC
14.16.1. COMPANY OVERVIEW
14.16.2. REVENUE ANALYSIS
14.16.3. PRODUCT PORTFOLIO
14.16.4. RECENT DEVELOPMENTS
14.17. ARTRON LABORATORIES, INC.
14.17.1. COMPANY OVERVIEW
14.17.2. REVENUE ANALYSIS
14.17.3. PRODUCT PORTFOLIO
14.17.4. RECENT DEVELOPMENTS
14.18. BIOMERIEUX SA
14.18.1. COMPANY OVERVIEW
14.18.2. REVENUE ANALYSIS
14.18.3. PRODUCT PORTFOLIO
14.18.4. RECENT DEVELOPMENTS
14.19. ENTOPSIS
14.19.1. COMPANY OVERVIEW
14.19.2. REVENUE ANALYSIS
14.19.3. PRODUCT PORTFOLIO
14.19.4. RECENT DEVELOPMENTS
14.20. LIFESIGN, LLC.
14.20.1. COMPANY OVERVIEW
14.20.2. REVENUE ANALYSIS
14.20.3. PRODUCT PORTFOLIO
14.20.4. RECENT DEVELOPMENTS
15. RELATED REPORTS
Looking for more information on this market? Click Here @ http://databridgemarketresearch.com/reports/point-care-testing-poct-market/
Other Market Insights:
The Global Molecular Spectroscopy Market, latest insights by Data Bridge Market Research states that the market is growing at CAGR of 5.0% in the forecast period 2017 to 2024, expected to reach USD 6.712 Billion by 2024.
Report Access : http://databridgemarketresearch.com/reports/global-molecular-spectroscopy-market/
About Data Bridge Market Research
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Vishal Dixit
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com